Next Article in Journal
Angiogenesis in Interstitial Lung Diseases
Previous Article in Journal
Common Variable Immunodeficiency in a Patient with Suspected Sarcoidosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 77
Issue 1
10.5603/ARM.27844
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Omalizumab, Recombinant Humanized Monoclonal Antibody Anti-IgE—New Fields of Studies on the Therapeutic Indications

by
Izabela Kupryś-Lipińska
* and
Piotr Kuna
Klinika Chorób Wewnętrznych Astmy i Alergii, Uniwersytecki Szpital Kliniczny Nr 1 im. Norberta Barlickiego w Łodzi, Uniwersytet Medyczny w Łodzi, 90-153 Łódź, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2009, 77(1), 43-51; https://doi.org/10.5603/ARM.27844
Submission received: 14 April 2008 / Revised: 19 December 2008 / Accepted: 19 December 2008 / Published: 19 December 2008

Abstract

Omalizumab is the monoclonal antibody against IgE, which blocks the binding of IgE to receptors on effector cells and this way blocks or decreases allergic reaction and asthma symptoms. Nowadays omalizumab is registered in the USA and European Union including Poland for treatment of patients with severe persistent, uncontrolled asthma. It is very effective in the reduction of asthma exacerbations, hospitalizations and emergency visits, it decreases intensity of symptoms and improves the quality of life. But omalizumab has more extensive action; given subcutaneously it has systemic effect. The article is the review of the studies and case reports on usage of omalizumab in new indications. Some authors’ own experiences in this field are also presented.
Keywords: omalizumab; choroby atopowe; alergiczny nieżyt nosa; atopowe zapalenie skóry; pokrzywka omalizumab; choroby atopowe; alergiczny nieżyt nosa; atopowe zapalenie skóry; pokrzywka

Share and Cite

MDPI and ACS Style

Kupryś-Lipińska, I.; Kuna, P. Omalizumab, Recombinant Humanized Monoclonal Antibody Anti-IgE—New Fields of Studies on the Therapeutic Indications. Adv. Respir. Med. 2009, 77, 43-51. https://doi.org/10.5603/ARM.27844

AMA Style

Kupryś-Lipińska I, Kuna P. Omalizumab, Recombinant Humanized Monoclonal Antibody Anti-IgE—New Fields of Studies on the Therapeutic Indications. Advances in Respiratory Medicine. 2009; 77(1):43-51. https://doi.org/10.5603/ARM.27844

Chicago/Turabian Style

Kupryś-Lipińska, Izabela, and Piotr Kuna. 2009. "Omalizumab, Recombinant Humanized Monoclonal Antibody Anti-IgE—New Fields of Studies on the Therapeutic Indications" Advances in Respiratory Medicine 77, no. 1: 43-51. https://doi.org/10.5603/ARM.27844

APA Style

Kupryś-Lipińska, I., & Kuna, P. (2009). Omalizumab, Recombinant Humanized Monoclonal Antibody Anti-IgE—New Fields of Studies on the Therapeutic Indications. Advances in Respiratory Medicine, 77(1), 43-51. https://doi.org/10.5603/ARM.27844

Article Metrics

Back to TopTop